XML 42 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair value measurement
12 Months Ended
Jun. 30, 2018
Text block1 [abstract]  
Fair value measurement

Note 26. Fair value measurement

Fair value hierarchy

The following tables detail the consolidated entity’s assets and liabilities, measured or disclosed at fair value, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly

Level 3: Unobservable inputs for the asset or liability

 

Consolidated - 2018    Level 1
A$’000
     Level 2
A$’000
     Level 3
A$’000
     Total
A$’000
 

Assets

           

Ordinary shares - listed

     3,680        —          —          3,680  

Unlisted options

     —          —          656        656  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Assets

     3,680        —          656        4,336  
  

 

 

    

 

 

    

 

 

    

 

 

 

Liabilities

           

Contingent Consideration

     —          —          2,558        2,558  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total liabilities

     —          —          2,558        2,558  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

Consolidated - 2017    Level 1
A$’000
     Level 2
A$’000
     Level 3
A$’000
     Total
A$’000
 

Assets

           

Ordinary shares - listed

     22        —          —          22  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Assets

     22        —          —          22  
  

 

 

    

 

 

    

 

 

    

 

 

 

Liabilities

           

Contingent Consideration

     —          —          4,019        4,019  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total liabilities

     —          —          4,019        4,019  
  

 

 

    

 

 

    

 

 

    

 

 

 

There were no transfers between levels during the financial year.

The fair value of contingent consideration related to the acquisition of Glioblast Pty Ltd and the licence agreement is estimated by probability-weighting the expected future cash outflows, adjusting for risk and discounting.

The effects on the fair value of risk and uncertainty in the future cash flows are dealt with by adjusting the estimated cash flows rather than adjusting the discount rate.